Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
HR+
•
Breast Cancer, Non-metastatic
Would you treat beyond 10 years of adjuvant hormonal therapy for premenopausal woman with high risk ER+ HER2 negative breast cancer who remain premenopausal at the end of 10 year adjuvant hormonal therapy?
What factors may influence your decision making?
Related Questions
What is your approach to adjuvant chemotherapy for a postmenopausal woman with pT1cN0 grade 2 ER+ breast cancer (IDC) and OncoType RS of 25?
Would you give adjuvant Tamoxifen to a premenopausal with ER+/PR+/HER2- Stage IA [pT1a, pN0(I+1)] breast cancer s/p bilateral mastectomies?
Would you offer adjuvant ribociclib to a postmenopausal female with ER+ luminal A, node+ breast cancer pT1cN1a grade 2 that didn't require chemotherapy per OncoType, but met NATALEE inclusion criteria?
Would you consider adding adjuvant ribociclib for a patient who has already received 2 years of endocrine therapy and is eligible for ribociclib according to the NATALEE trial?
What adjuvant therapy would you recommend for a woman in her 90s with ER-positive, HER2-positive breast cancer who received neoadjuvant trastuzumab, pertuzumab, and anastrozole, but did not achieve a pathologic complete response?
What additional risk features, if any, would sway you to offer chemotherapy in premenopausal women with ER+ HER2- node positive patients whose Oncotype is < 11?
What are your top takeaways in Medical Oncology from SABCS 2024?
Is there evidence supporting the use of nab-paclitaxel in place of paclitaxel in the KEYNOTE-522 neoadjuvant regimen for triple-negative breast cancer, in cases of paclitaxel hypersensitivity?
What neoadjuvant chemotherapy do you suggest for a rapidly growing triple-negative breast cancer?
Given the new ASCO guidelines on SNB in early stage breast cancer, how does the omission of SNB in patients aged 50-70 impact your adjuvant radiation recommendations?